跳至主要内容
临床试验/NCT00679653
NCT00679653已完成3 期

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

Abbott0 个研究点目标入组 171 人开始时间: 2002年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Abbott
入组人数
171
主要终点
Systolic Blood Pressure

研究概览

简要总结

To study the effect of sibutramine treatment on weight reduction and blood pressure improvement in three groups with antihypertensive therapy whose blood pressure was not adequately controlled with antihypertensive combination treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treated essential hypertension.
  • Obesity: BMI 27-35 kg/m2

排除标准

  • Secondary hypertension.
  • Stage 3 hypertension.
  • Secondary obesity; BMI > 35kg/m
  • CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial fibrillation; myocarditis.
  • Kidney failure.
  • Liver failure.
  • Hyperthyroidism.
  • Unstable DM.
  • Carcinoma.
  • Severe chronic infectious disease.
  • Alcohol or drug abuse.
  • Pregnancy.
  • Epilepsy.
  • Psychosis or treatment with antidepressants or major tranquilizers

研究组 & 干预措施

3

Active Comparator

felodipine/ramipril

干预措施: felodipine/ramipril (Drug)

1

Active Comparator

verapamil/trandolapril

干预措施: sibutramine (Drug)

1

Active Comparator

verapamil/trandolapril

干预措施: verapamil/trandolapril (Drug)

2

Active Comparator

metoprolol/HCT

干预措施: sibutramine (Drug)

2

Active Comparator

metoprolol/HCT

干预措施: metoprolol/HCT (Drug)

3

Active Comparator

felodipine/ramipril

干预措施: sibutramine (Drug)

结局指标

主要结局

Systolic Blood Pressure

时间窗: Duration of Study

Diastolic Blood Pressure

时间窗: Duration of Study

次要结局

未报告次要终点

研究者

发起方
Abbott
申办方类型
Industry

相似试验